The Boston-based team at Dechert has notable capabilities advising its clientele on the patent-related aspects that underpin significant financial transactions. Further, it handles strategy, prosecution, and implementation elements of various patents. Andrea Reid and Andrew Wilkins co-head the offering; Reid has expertise in life sciences matters while Wilkins specializes in the management of portfolios relating to large molecules. Chad Davis‘ workload includes handling IP risk assessments, due diligence aspects, and the handling of the prosecution and development of patent portfolios. John Rearick also advises on patent due diligence, particularly in the life sciences space.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Good quality service and very direct communicators and collaborators. Willing to try new and interesting protection strategies. Clear and transparent. Smart staffing for complex projects with usually just 2-3 involved with appropriate leveling of work. Very happy overall.’
‘Andrew Wilkins and Sean Coughlin are the core team supporting us. They are all highly responsive, which is important as the core business is outside of the US.'
‘Dechert is an expert in small-molecule IP, especially the field of induced proximity. They can develop a fit-for-purpose strategy to ensure that your IP and defensive IP is filed aggressively and robustly.’
‘Chad is pleasant to work with and always available for key input. He is great with the scientists, but also with investors.’
'The Dechert team that we work with is predominantly individuals who have been trained as organic chemists - they speak our language and understand very well how to position IP to our advantage.’
‘Incredibly responsive, and expertise that is both broad and deep.’
Key clients
- Agenus
- Andera Partners
- argenx SE
- Delphia Therapeutics
- Forbion Capital Partners
- Halda Therapeutics
- Homology Medicines
- Neurocrine Biosciences
- Nimbus Therapeutics
- Novo Holdings A/V
Work highlights
Handled the patent strategy and implementation for Boston-based X4 Pharmaceuticals’, a late-stage clinical biopharmaceutical company, approved product XOLREMDI™ (mavorixafor), the first drug approved to treat rare disease WHIM syndrome.
Handled world patent prosecution and patent strategy for argenx SE’s approved product VYVGART® Hytrulo for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Handled the entire patent portfolio underpinning a $210m private financing for Nimbus Therapeutics.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Andrea Reid; Andrew Wilkins
Other key lawyers
Sean Coughlin; Chad Davis; John Rearick